Compare

BPC-157 (Oral) vs TB-500 Fragment

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

BPC-157 (Oral)

752 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 56% · Mixed 28% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite control
15
Energy
124
Mood
161
Focus
188
Sleep quality
124

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

GI discomfort
111
Dizziness
24
Fatigue
126
Nausea
183
Water retention
123

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 200–400 mcg

Reports span 10–600 mcg

10–25
2
25–50
5
50–100
10
100–200
16
200–400
17
400–600
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing36stacking19side effects22bpc-157 (oral)10

How repeat users are trending

Among repeat reporters, 66% said they felt similar to their last entry, 42% more positive, and 16% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 16 days · Based on 165 repeat reporters

TB-500 Fragment

1497 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 51% · Mixed 32% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Focus
156
Sleep quality
30
Lean mass
59
Joint comfort
175
Recovery
122

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
72
Water retention
109
Appetite loss
24
Injection site reaction
171
Anxiety
121

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 200–400 mcg

Reports span 25–1000 mcg

25–50
2
50–100
5
100–200
10
200–400
20
400–600
15
600–1000
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing21stacking19side effects17tb-500 fragment30

How repeat users are trending

Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 23 days · Based on 329 repeat reporters

Sources (7)

Published sources linked on the BPC-157 (Oral) and TB-500 Fragment wiki pages.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  3. PubMed

    Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions

    Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011

    Source
    Wiki study page →
  4. PubMed

    Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions

    Tlak Gajger I, Ribarić J, Smodiš Škerl M, et al. Journal of veterinary pharmacology and therapeutics. 2018

    Source
    Wiki study page →
  5. PubMed

    Thymosin beta4: a multi-functional regenerative peptide (review)

    Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012

    Source
    Wiki study page →
  6. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  7. PubMed

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026

    Source
    Wiki study page →